Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02261493 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 787
- Enrollment target
NCT02261493: Completed Phase 3 study, sponsored by Allergan.
NCT02261493 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 787 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02261493, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 787 participants
- Enrollment target
Study Summary
This is a safety and efficacy study of onabotulinumtoxinA in subjects with upper facial rhytides (forehead lines, glabellar lines, lateral canthal lines \[crow's feet lines\]).
Primary Outcome
The Investigator and subject each assessed the severity of the subject's forehead lines at maximum eyebrow elevation using the 4-grade FWS, where 0=none, 1=mild, 2=moderate, and 3=severe. The percentage of subjects with at least a 2-grade improvement from baseline assessed by both the Investigator and the subject are reported.
Interventions
- DRUG Normal Saline
- BIOLOGICAL OnabotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 787 participants |
| Start Date | 2014-10-27 |
| Est. Completion | 2016-04-20 |
| Phase | Phase 3 |
What the finished NCT02261493 record still lists
NCT02261493 is an interventional study that assigns participants to a tested intervention. The registered 787 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.
NCT02261493 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02261493 about?
NCT02261493 is a clinical study titled "A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides". This is a safety and efficacy study of onabotulinumtoxinA in subjects with upper facial rhytides (forehead lines, glabellar lines, lateral canthal lines \[crow's feet lines\]).
What is the current status of trial NCT02261493?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 787 participants. The study started on 2014-10-27. Estimated completion is 2016-04-20.
What interventions are being tested in trial NCT02261493?
The interventions under investigation include: Normal Saline (DRUG), OnabotulinumtoxinA (BIOLOGICAL).
Who is sponsoring clinical trial NCT02261493?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02261493's enrollment target sits among peer trials
787 431st of 2000 higher than 1,570 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06488781 · 787 participants · Phase 2
Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0
- NCT06876649 · 787 participants · Phase 4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- NCT07276724 · 786 participants · Phase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
- NCT07359846 · 786 participants · Phase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI